Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.
Frankenberger B, Regn S, Geiger C, Noessner E, Falk CS, Pohla H, Javorovic M, Silberzahn T, Wilde S, Buchner A, Siebels M, Oberneder R, Willimsky G, Pezzutto A, Blankenstein T, Schendel DJ. Frankenberger B, et al. Among authors: pezzutto a. World J Urol. 2005 Jul;23(3):166-74. doi: 10.1007/s00345-005-0505-5. Epub 2005 Jul 5. World J Urol. 2005. PMID: 15997395 Review.
Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ. Buchner A, et al. Among authors: pezzutto a. Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192. Hum Gene Ther. 2010. PMID: 19788391 Clinical Trial.
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.
Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ. Pohla H, et al. Among authors: pezzutto a. Mol Med. 2013 Feb 8;18(1):1499-508. doi: 10.2119/molmed.2012.00221. Mol Med. 2013. PMID: 23269976 Free PMC article. Clinical Trial.
Allogeneic vaccination for renal cell carcinoma: development and monitoring.
Pohla H, Frankenberger B, Stadlbauer B, Oberneder R, Hofstetter A, Willimsky G, Pezzutto A, Dörken B, Blankenstein T, Schendel DJ. Pohla H, et al. Among authors: pezzutto a. Bone Marrow Transplant. 2000 May;25 Suppl 2:S83-7. doi: 10.1038/sj.bmt.1702362. Bone Marrow Transplant. 2000. PMID: 10933197
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.
Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A. Westermann J, et al. Among authors: pezzutto a. Gene Ther. 2011 Apr;18(4):354-63. doi: 10.1038/gt.2010.143. Epub 2010 Nov 11. Gene Ther. 2011. PMID: 21068778 Clinical Trial.
Direct and indirect T cell priming by dendritic cell vaccines.
Cayeux S, Richter G, Becker C, Pezzutto A, Dörken B, Blankenstein T. Cayeux S, et al. Among authors: pezzutto a. Eur J Immunol. 1999 Jan;29(1):225-34. doi: 10.1002/(SICI)1521-4141(199901)29:01<225::AID-IMMU225>3.0.CO;2-W. Eur J Immunol. 1999. PMID: 9933104 Free article.
Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.
Flörcken A, Grau M, Wolf A, Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J. Flörcken A, et al. Among authors: pezzutto a. Int J Cancer. 2015 Apr 15;136(8):1814-26. doi: 10.1002/ijc.29230. Epub 2014 Sep 30. Int J Cancer. 2015. PMID: 25242680 Free article.
156 results